ArticleMicrobiology spectrum2026
CasCADE: Cas
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The adaptation of CRISPR technologies for molecular detection marks a significant advancement in the field of biosurveillance and infectious disease response. CRISPR-based detection systems offer superior specificity and sensitivity compared to traditional PCR methods by directly binding and cleaving target DNA or RNA sequences, thus signaling the presence of specific pathogens. These advantages include the elimination of non-specific amplification and the reduction of required genetic material, leading to faster time to results without the need for extensive amplification cycling. However, the efficacy of CRISPR technologies heavily depends on the design of specific guide RNA (gRNA) sequences tailored for each genomic target, a process that can be intricate and time-consuming. We present Cas-CRISPR Automated Design and Evaluation (CasCADE), a state-of-the-art gRNA design software platform with a high degree of flexibility and modularity. CasCADE incorporates k-mer set operations to reduce time to answer for large data inputs when compared to computationally costly multiple sequence alignment methodologies and uses an agnostic whole genome approach to maximize gRNA discovery. CasCADE can be scaled efficiently to problems of any input sequence size and can be used for design, candidate evaluation, or both, depending on user need. IMPORTANCE: This work describes our software pipeline Cas-CRISPR Automated Design and Evaluation (CasCADE) that allows for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.